Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
Kedudukan dalam Saham #93
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and... Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Harga Saham
$137.21
Modal Pasaran
$170.34B
Perubahan (1 hari)
-2.76%
Perubahan (1 tahun)
28.14%
Negara
US
Perdagangan Gilead Sciences, Inc. (GILD)

Kategori

Pendapatan untuk Gilead Sciences, Inc. (GILD)
Pendapatan pada Dec 2025 TTM: $9.80B
Menurut laporan kewangan terkini Gilead Sciences, Inc., pendapatan semasa syarikat ialah $9.80B. Pada tahun 2024, syarikat memperoleh pendapatan sebanyak $690.00M, penurunan berbanding pendapatan pada tahun 2023 yang berjumlah $6.86B. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Gilead Sciences, Inc. dari 2000 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $9.80B 0.01%
2025 $9.80B 1,319.71%
2024 $690.00M -89.94%
2023 $6.86B 17.97%
2022 $5.81B -29.77%
2021 $8.28B 395.99%
2020 $1.67B -67.66%
2019 $5.16B -33.84%
2018 $7.80B -42.35%
2017 $13.53B -20.87%
2016 $17.10B -21.06%
2015 $21.66B 45.79%
2014 $14.86B 253.04%
2013 $4.21B 16.50%
2012 $3.61B -1.07%
2011 $3.65B -6.71%
2010 $3.91B 11.75%
2009 $3.50B 31.03%
2008 $2.67B 17.72%
2007 $2.27B -455.74%
2006 $-638.21M -154.93%
2005 $1.16B 76.99%
2004 $656.42M -491.82%
2003 $-167.53M -328.26%
2002 $73.40M 27.76%
2001 $57.45M -237.08%
2000 $-41.91M 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
$25.73B 162.63%
US
$12.40B 26.59%
GB
$32.58B 232.56%
US
$6.60B -32.66%
US
$16.35B 66.91%
CH